Nabla and Proteotype Show Who Controls the Workflow Layer

The competitive edge in medical devices is moving upstream to the layer that decides how data is normalized, routed, and made operational.

Updated

What is this trend?

Control is shifting from the device itself to the workflow layer that normalizes, routes, and operationalizes device data inside EHRs and analytics systems.

  • EHR integration is becoming the real competitive moat.
  • Normalization and routing decide where data becomes clinically useful.
  • Test-specific orchestration beats generic telemetry pipes.
  • Governance and interoperability are now procurement criteria.
  • Value is moving to platforms that prove downstream usability.

What’s the latest?

Nabla is tying into the dominant EHR stack, while Proteotype is building a test-specific, jurisdiction-aware orchestration layer rather than a generic telemetry pipe.

Robotic Surgery Scales, Workflow Control Tightens, and Regional Manufacturing Becomes a Moat

How it developed

  1. Integrated robotics, portfolio separations, governed device data, and QMSR compliance become competitive moats
    • Device Data Shifts from Product Feature to Governed Service Layer

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Medical Devices & Tools

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.